DSCSA Suspect Product: Pharmacy Quarantine and Investigation Steps

A suspect product is one for which there is reason to believe it may be counterfeit, diverted, stolen, intentionally adulterated, or otherwise unfit. Under DSCSA, a pharmacy must quarantine a suspect product and promptly investigate, coordinating with trading partners as needed. If it is determined to be illegitimate, notification and disposition duties follow; escalate rather than returning it to stock.

Suspect and illegitimate are different stages

A suspect product is one that gives a trading partner reason to believe it may be illegitimate. It is a trigger to investigate, not a final conclusion. An illegitimate product is one for which credible evidence supports the statutory criteria, such as counterfeit, diverted or stolen status, intentional adulteration causing serious risk, fraudulent transaction, or being unfit for distribution with likely serious consequences. The distinction matters because a suspicion calls for containment and investigation; a determination triggers additional actions.

Recognize signals

FDA guidance describes risk factors that can include a product with an altered or missing label, questionable packaging, an unexplained sale by an unauthorized source, product identifiers that do not match, or information that a package was stolen or diverted. A visual concern does not prove illegitimacy, but it must be taken seriously. Staff should know how to report a concern even if the product is not yet confirmed.

Quarantine promptly

If a product is suspect, remove it from available inventory and segregate it so it cannot be dispensed or redistributed while the investigation proceeds. Use a clearly marked, access-controlled area or system hold according to SOP. Preserve packaging and identifiers; do not discard or relabel evidence. Keep the product in conditions that protect its integrity unless the authorized investigation directs otherwise. Notify the pharmacist, compliance contact, or designated DSCSA lead immediately.

Investigate with the right information

The pharmacy should review package identifiers, transaction data, supplier identity, invoices, receiving records, recall notices, and the circumstances that raised concern. Contact the immediate trading partner or manufacturer through verified contact details, not only those printed on a suspicious package. FDA may request information through its DSCSA portal during an investigation or recall. Record who was contacted, what was checked, when responses arrived, and the determination.

If the product is cleared

If investigation supports that the product is not illegitimate, the authorized person can release it from quarantine following the written SOP and any supplier or regulator instructions. Document the rationale and disposition. Do not return it to inventory based solely on a brief phone assurance when required verification has not been completed. If uncertainty remains, keep it on hold and escalate.

If it is determined illegitimate

FDA states trading partners, including dispensers, must notify FDA and appropriate immediate trading partners within 24 hours after determining a product is illegitimate. The product must remain quarantined and be dispositioned to prevent further distribution. Use FDA’s current notification process, which includes the 3911 platform or Form FDA 3911. Coordinate with the manufacturer and trading partners and follow regulatory directions about termination of a notification.

Do not confuse product quality reporting with supply-chain notification

A suspected adverse event or product-quality concern may also be reported through FDA’s MedWatch program, depending on circumstances. DSCSA Form 3911 addresses illegitimate product notifications in the drug supply chain. The two reporting pathways serve different purposes. The pharmacy’s compliance lead or pharmacist should decide what reports are required; do not assume filing one automatically fulfills the other.

Example: inconsistent identifier

A package’s 2D product identifier does not match the expected NDC or lot information in the trading partner’s record. Staff stop dispensing the package, isolate it, preserve its packaging, and notify the compliance lead. The lead checks the source records and contacts the authorized supplier. If the mismatch is resolved and the product is confirmed legitimate, the release is documented. If credible evidence establishes illegitimacy, notification and final disposition procedures begin.

PTCE takeaway

Suspect means investigate; illegitimate means credible evidence supports the statutory criteria. Quarantine early, preserve trace records, work through authorized contacts, document the conclusion, and make required notifications if illegitimacy is determined.

Operational checks that prevent mix-ups

The quarantine itself needs enough specificity to prevent a mistaken release. Label the hold with the product, package or lot identifier, date, reason for hold, and the person or team responsible. Block affected stock in the inventory system as well as physically segregating it when possible. Preserve the outside packaging, shipping documents, and any barcode scan data. If the suspected package was already dispensed, alert the pharmacist and compliance lead immediately so they can assess patient contact and notification needs. Do not contact a patient with an unverified conclusion or discard evidence. During the investigation, track each communication and set a follow-up owner; unresolved cases can otherwise disappear between shifts. Once the authorized person documents a disposition, remove the hold only through the approved process and retain the decision with the trace records.

Scope and handoff details

An investigation should also consider whether the pharmacy has received other packages from the same lot or source, whether a recall or FDA alert exists, and whether the product has already left the pharmacy. The goal is to define the scope before anyone releases related stock. Ask the supplier for verification through a trusted channel and record the case number. If the package is associated with a broader alert, follow the exact scope in that alert rather than relying only on a single barcode scan. When the investigation is completed, preserve the evidence and final decision for the applicable records period. The technician’s best contribution is prompt observation, accurate handling, and a clean chronology—not trying to prove authenticity alone.

Points to carry into practice

• Check the current FDA or DEA source and the pharmacy SOP for the exact requirement.
• Hold and escalate an unresolved discrepancy instead of guessing or bypassing a control.